Edwin Charlebois, MPH, PhD

CTSI Profile Photo

Edwin Charlebois, MPH, PhD

User Profile Name
Professor, School of Medicine
CTSI Profile Title
User Profile Email

Biography

As a senior scientist at the UCSF Center for AIDS Prevention Studies (CAPS) my research program focuses on the epidemiology and prevention of HIV infection and its consequences. Overarching this focus are translational science efforts to improve the methodology and evaluation of research and interventions aimed at controlling and eventually eliminating the domestic and international spread of HIV. Domestic HIV Research: My most recent domestic HIV prevention research is an evaluation of the potential effect of expanded ART and HIV testing strategies on reducing the number of new HIV infections in San Francisco. In this computational biology modeling paper published in CID in 2011 (with an accompanying editorial) we estimated significant reductions in new HIV infections are likely with expanded HIV treatment of those already in care and even greater gains with more frequent at-risk community HIV testing. This research along with the results of recent clinical trials were cited as evidence for a change in treatment policy in San Francisco to offer ART to all HIV infected persons. Our studies relate well with a recent editorial we published in 2010 in Archives of Internal Medicine wherein we highlight the importance of linking HIV infected persons into care and the associated potential HIV prevention benefits. Another priority research area for me is the development of methods for the evaluation of combination HIV prevention interventions. Combination HIV prevention interventions are specifically called for in the US National HIV/AIDS Strategy (NHAS) and specific evaluation methods for them have been identified as significant scientific gap in our recently published 2011 editorial in JAIDS on setting the NIH research agenda for the NHAS. Specifically, I have received developmental funding to pursue novel evaluation methods for community-level combination HIV prevention interventions that involve surveillance measurements of community HIV viral load, intervention process measures and structural equation modeling. In addition I will be co-directing a research team assisting in the evaluation of the San Francisco implementation of the HRSA and CDC’s 12-city project – a combination HIV prevention intervention comprising 14 interventions. In the fall of 2011 I will be leading a national round-table on the state-of-the-art and future research directions for evaluation methods for combination HIV prevention interventions to be hosted by the UCSF Center for AIDS Prevention Studies. International HIV Research: Internationally, my research focus is on HIV and co-infections/interaction with Tuberculosis and Malaria. Primarily working in East Africa, I am Principal Investigator of three NIH sponsored grants and co-investigator on several more. I am currently studying effective strategies for diagnosing HIV among outpatient TB evaluation patients and their family and household members in a 2,000 person randomized trial of home-based versus TB clinic based HIV testing and utilization of same-day rapid HIV tests. I am also involved in studying interactions between HIV protease inhibitor treatment and malaria incidence in two additional randomized HIV treatment trials among HIV infected children and HIV infected pregnant women. On a broader scale I am co-leading the development of a three country research collaboration, SEARCH (Sustainable East Africa Research in Community Health) to study the community level effectiveness of a program of community-wide HIV testing and universal HIV treatment to all HIV infected persons and its effect on HIV, TB, Malaria incidence and community economic and educational productivity. My area of research within the collaboration focuses on the 40 community-cluster randomized design, its HIV specific end-points of HIV incidence and community HIV viral load, and the development and evaluation of streamlined HIV care and evaluation. Training the Next Generation of HIV Scientists: An important part of my research program is training and mentoring the next generation of HIV scientists. As the principal investigator of 2 large international data management and statistical support cores (one for a NICHD supported program project, and one for a NIAID funded International Center for Excellence in Malaria Research, ICEMR) – I am able to organize and support the cores as a resource for training and mentoring post-doctoral researchers and medical students in international HIV and clinical research. Through individual level research mentorship, a weekly international investigators seminar held in the US, the UCSF CAPS Traineeship in AIDS Prevention Studies (TAPS) program, and affiliated NIH K training grants, I supervise and assist between 3-5 trainees annually in the development of individual research projects, and epidemiologic and biostatistical training.
CTSI Profile Bio

Displaying 201 - 225 of 233

  1. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med. 2004 Apr; 19(4):357-65.
  2. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004 Mar-Apr; 5(2):74-9.
  3. Liechty CA, Alexander CS, Harrigan PR, Guzman JD, Charlebois ED, Moss AR, Bangsberg DR. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS. 2004 Jan 02; 18(1):127-9.
  4. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004 Jan 02; 18(1):81-8.
  5. Johnson MO, Catz SL, Remien RH, Rotheram-Borus MJ, Morin SF, Charlebois E, Gore-Felton C, Goldsten RB, Wolfe H, Lightfoot M, Chesney MA. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS. 2003 Dec; 17(12):645-56.
  6. David R. Bangsberg, Frederick M. Hecht, Edwin D. Charlebois, Margaret Chesney, Andrew Moss. Comparing Objective Measures of Adherence to HIV Antiretroviral Therapy: Electronic Medication Monitors and Unannounced Pill Counts. AIDS and Behavior. 2001 Sep 1; 5(3):275-281.
  7. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 2001 Aug 04; 358(9279):368-74.
  8. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001 Jun 15; 15(9):1181-3.
  9. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, Moss A. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001 Apr 15; 26(5):435-42.
  10. David R. Bangsberg, Frederick M. Hecht, Heather Clague, Edwin D. Charlebois, Dan Ciccarone, Margaret Chesney, Andrew Moss. Provider Assessment of Adherence to HIV Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001 Apr 1; 26(5):435-442.
  11. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000 Mar 10; 14(4):357-66.
  12. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht FM, Yajko D, Ng V, Hadley K. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol. 2000 Mar; 38(3):1113-20.
  13. Morin SF, Charlebois ED. Expanding access to early HIV care: new challenges for federal health policy. AIDS Public Policy J. 2000; 15(2):65-74.
  14. Kohl S, Charlebois ED, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich RE, Langenberg AG, Burke RL. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis. 2000 Jan; 181(1):335-9.
  15. Grant RW, Charlebois ED, Wachter RM. Risk factors for early hospital readmission in patients with AIDS and pneumonia. J Gen Intern Med. 1999 Sep; 14(9):531-6.
  16. David R. Bangsberg, Frederick M. Hecht, Edwin D. Charlebois, Margaret Chesney, Andrew Moss. Comparing Objective Measures of Adherence to HIV Antiretroviral Therapy: Electronic Medication Monitors and Unannounced Pill Counts. AIDS and Behavior. 2001 Sep 1; 5(3):275-281.
  17. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet. 2001 Aug 04; 358(9279):368-74.
  18. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001 Jun 15; 15(9):1181-3.
  19. Kohl S, Sigaroudinia M, Charlebois ED, Jacobson MA. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells. J Infect Dis. 1996 Nov; 174(5):1105-8.
  20. David R. Bangsberg, Frederick M. Hecht, Heather Clague, Edwin D. Charlebois, Dan Ciccarone, Margaret Chesney, Andrew Moss. Provider Assessment of Adherence to HIV Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001 Apr 1; 26(5):435-442.
  21. ROBERT M. WACHTER, JOHN M. LUCE, SHARON SAFRIN, DANIEL C. BERRIOS, EDWIN CHARLEBOIS, ANNE A. SCITOVSKY. Cost and Outcome of Intensive Care for Patients with AIDS, Pneumocystis carinii Pneumonia, and Severe Respiratory Failure. Survey of Anesthesiology. 1996 Apr 1; 40(2):75-76.
  22. Wachter RM, Luce JM, Safrin S, Berrios DC, Charlebois E, Scitovsky AA. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA. 1995 Jan 18; 273(3):230-5.
  23. Northfelt DW, Charlebois ED, Mirda MI, Child C, Kaplan LD, Abrams DI. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jan 01; 8(1):45-50.
  24. Veugelers PJ, Page KA, Tindall B, Schechter MT, Moss AR, Winkelstein WW, Cooper DA, Craib KJ, Charlebois E, Coutinho RA. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol. 1994 Oct 15; 140(8):747-58.
  25. Jenkins M, Landers D, Williams-Herman D, Wara D, Viscarello RR, Hammill HA, Kline MW, Shearer WT, Charlebois ED, Kohl S. Association between anti-human immunodeficiency virus type 1 (HIV-1) antibody-dependent cellular cytotoxicity antibody titers at birth and vertical transmission of HIV-1. J Infect Dis. 1994 Aug; 170(2):308-12.